Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Launchbluebird bio, Inc. presents new long-term data on gene therapy for sickle cell disease and beta-thalassemia at the 66th ASH Annual Meeting.
Nov 05, 2024
SomervilleBiotechnologyHealth CareTherapeutics
Product Description
bluebird bio, Inc. announced the presentation of updated long-term follow-up data from its gene therapy programs for sickle cell disease and beta-thalassemia at the upcoming ASH Annual Meeting in December 2024, showcasing the potential of its gene therapies.
Company Information
Company
bluebird bio
Location
455 Grand Union Boulevard
Somerville, Massachusetts, United States
About
bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment bluebird bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.